FindTrial
Sign In

Body surface area (BSA) &gt

2 trials

Sponsors

Gifu University

Conditions

Intractable Lymphatic AnomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations

Phase 3

A multicenter, phase 3 study assessing efficacy and safety of the Sirolimus in the Treatment of intractable lymphatic anomalies (SILA study)
Active, not recruitingJPRN-UMIN000028905
Gifu UniversityIntractable Lymphatic Anomalies
Start: 2017-10-01Target: 10Updated: 2026-06-29

Unknown Phase

A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies
Active, not recruitingJPRN-UMIN000030522
Gifu UniversityIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations
Start: 2017-11-14Target: 50Updated: 2026-06-29

Related Papers

Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).
2019-01-1423 citations